Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
about
Risk determination and prevention of breast cancerPhysician and Patient Barriers to Breast Cancer Preventive TherapyTools of the trade: individualized breast cancer risk assessment.Qualitative Versus Quantitative Mammographic Breast Density Assessment: Applications for the US and AbroadDevelopment of an electronic breast pathology database in a community health system.Risk-benefit profiles of women using tamoxifen for chemoprevention.Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot StudyNovel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers StudyChemoprevention for Breast Cancer.Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer PatientsThe contributions of breast density and common genetic variation to breast cancer riskUsing Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial.Affective forecasting and medication decision making in breast-cancer preventionUptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.Cancer Prevention: Obstacles, Challenges and the Road Ahead.Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study.PAD in women: the ischemic continuum.Combining quantitative and qualitative breast density measures to assess breast cancer risk.Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.Breast cancer risk prediction using a clinical risk model and polygenic risk score.Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.FSCN1 gene polymorphisms: biomarkers for the development and progression of breast cancer.Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.HMGB1 genetic polymorphisms are biomarkers for the development and progression of breast cancer.Evaluation of 2 breast cancer risk models in a benign breast disease cohort
P2860
Q26991921-74FC0CFF-4FCF-4763-83F9-AACE77F501DFQ28072526-F6D30030-AFCD-4E7C-A0F2-845EF43FAD3BQ33571603-86F2B5AB-345B-4E66-A620-304ADC043D9EQ33850485-E028262F-D854-4DEF-AF31-0CBB3551F867Q34077507-DEB01EA8-3515-4A08-9ECE-865F25CD7288Q34974865-42D87343-E6B7-420E-86C5-9BECE7A1ACFEQ35744037-20AAD6E1-585E-4476-BB05-33ECC5516B68Q35866151-C308F676-878C-4766-9B0B-121F53E2AC0CQ35892049-8902CA2E-161F-4774-80CB-5AF2F86E6054Q35998680-3F834049-AD42-4465-9061-7BE0177FAE08Q36090967-A98E35BB-0FD0-4D0A-A15B-1DDE163483DCQ36112872-5D94EF19-CCB0-4E01-9276-4101208A76C5Q36137764-01DEA0D0-75E4-40F7-88FD-D30396D86F9BQ36255311-939A34B0-A7DD-4BF9-9144-896221EB947AQ36422319-4C3080A1-65C8-4447-A203-9096A9479616Q36905513-FCC15E3B-0A19-4F2B-8F80-62591F91D715Q36947842-481051EC-81FA-4EAC-8D95-7C609417C921Q37002946-0AA89D55-1626-4BAC-9BE5-E60FB1AB99E0Q37454802-DAD89386-8AAB-46E3-B939-6CB2B200ABC5Q38458065-5382AD45-EACC-4D2C-8EB5-3664B56316B8Q38613626-569EF56F-E6EA-4C41-9B92-32DF4B15A987Q40089754-C8F9EC1D-6C4D-4B32-9971-E9E8F24E0BACQ40605693-00FBD8B8-3E39-4AB8-8784-D82AA7232306Q41696217-8CAE399C-7565-47AB-9BC8-1CE5EB8627E6Q47094857-E1316825-73B4-4A81-B9DA-5ABD8F284840Q48029327-E0D9EB9D-0C4E-4773-84B0-41E91DD7CC64Q51102156-8A9F6530-5F59-40B5-A9DB-44402A754AD5Q51837751-67D226B5-7766-42A4-B858-671123E4A8F9Q55264202-BAC19416-BA61-46F8-B4A8-F00B9D055F68Q57171683-7736F9FB-4AC8-4D61-8C1B-7149B7C01E54
P2860
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Medications to decrease the ri ...... orce recommendation statement.
@ast
Medications to decrease the ri ...... orce recommendation statement.
@en
Medications to decrease the ri ...... orce recommendation statement.
@nl
type
label
Medications to decrease the ri ...... orce recommendation statement.
@ast
Medications to decrease the ri ...... orce recommendation statement.
@en
Medications to decrease the ri ...... orce recommendation statement.
@nl
prefLabel
Medications to decrease the ri ...... orce recommendation statement.
@ast
Medications to decrease the ri ...... orce recommendation statement.
@en
Medications to decrease the ri ...... orce recommendation statement.
@nl
P1476
Medications to decrease the ri ...... orce recommendation statement.
@en
P2093
U.S. Preventive Services Task Force
Virginia A Moyer
P304
P356
10.7326/0003-4819-159-10-201311190-00717
P407
P577
2013-11-01T00:00:00Z